ALVO — Alvotech
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1898416 ·
Last close
$3.91
Market Cap
$1.22B
52W High
$4.59
52W Low
$2.94
ADV30
855,172
Next earnings
2026-05-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 105,865,000 | 59,778,000 | 9,674,000 | 1,030,000 | 1,421,168,000 | 63,832,000 | 1,703,480,000 |
| Dec 2025 | 166,573,000 | 105,293,000 | 48,255,000 | -108,547,000 | 1,487,099,000 | 172,359,000 | 1,771,586,000 |
| Sep 2025 | 113,744,000 | 78,738,000 | 1,313,000 | -5,252,000 | 1,409,178,000 | 42,848,000 | 1,585,941,000 |
| Jun 2025 | 173,239,000 | 99,414,000 | 18,057,000 | 32,038,000 | 1,392,754,000 | 151,452,000 | 1,566,082,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,197,000
Investing CF
$-104,215,000
Financing CF
$270,832,000
CapEx
$-96,129,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,409,790,000
Inventory
$220,054,000
Receivables
$153,786,000
ST Investments
—
EBIT TTM
$273,218,000
Pretax Income TTM
$136,348,000
Interest Exp TTM
$136,870,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$562,043,008
EBITDA
$104,241,000
Free Cash Flow
$-92,554,376
Enterprise Value
$2,601,481,728
Total Cash
$63,832,000
Total Debt
$1,457,281,024
Shares Out
312,048,292
Trailing EPS
$-0.29
Book Value
$-0.91
ROE
—
ROA
3.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 586,321,000 | 78,207,000 | 27,919,000 | 1,487,099,000 | 1,771,586,000 | — | -50,197,000 |
| Dec 2024 | 489,682,000 | 69,644,000 | -231,864,000 | 1,221,400,000 | 1,634,171,000 | — | -236,843,000 |
| Dec 2023 | 91,434,000 | -354,860,000 | -551,731,000 | 950,090,000 | 1,882,583,000 | — | -312,185,000 |
| Dec 2022 | 83,029,000 | -346,442,000 | -513,580,000 | 828,443,000 | 1,392,859,000 | — | -312,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. | $1.24B | $26.45 | — |
| IMTX | Immatics N.V. | $1.30B | $9.52 | — |
| MAZE | Maze Therapeutics, Inc. | $1.37B | $24.84 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.38B | $94.20 | — |
| IMCR | Immunocore Holdings plc | $1.45B | $28.55 | — |
News headlines (Yahoo Finance, 1h cache)
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Fed Policy Meeting
2026-06-16 12:34 · Yahoo
Alvotech Prices Share Offering, Private Placement
2026-06-16 08:11 · Yahoo
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
2026-06-16 03:59 · Yahoo
Alvotech Launches Public Offering, Private Placement of Ordinary Shares
2026-06-15 20:28 · Yahoo
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
2026-06-15 20:01 · Yahoo
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
2026-06-10 19:02 · Yahoo
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)
2026-06-08 10:41 · Yahoo
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
2026-06-08 08:00 · Yahoo
How The Investment Story For Alvotech (ALVO) Is Shifting Without New Analyst Guidance
2026-06-07 02:12 · Yahoo
Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection
2026-06-06 15:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.